On June 1, Arcus Biosciences presented the first data for casdatifan plus cabozantinib in oral metastatic kidney cancer, which showed a confirmed response.

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry ...

Arcus Biosciences’ focus on innovative cancer therapies and its promising clinical data make it an attractive candidate for partnerships or potential acquisition.

Get Ready for the ‘Trump Is Senile’ News Cycle President Donald Trump arrives for a House Republican meeting at the U.S. Capitol in Washington, D.C., May 20, 2025.(Tasos Katopodis/Getty Images) ...

Addepar, the data platform for wealth, investment, and asset management, announced the acquisition of Arcus, an enterprise AI workflow platform. Terms of the transaction were not disclosed. “Addepar ...

Arcus acquired a majority stake in FixMap in September Net is the second add-on under Arcus’ ownership FixMap is a Polish FTTH operator founded in 2018 Arcus Infrastructure Partners portfolio ...

Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update Data from the Phase 1/1b ARC-20 study cohort evaluating casdatifan plus cabozantinib in immunotherapy ...

Arcus Biosciences (NYSE:RCUS) will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Arcus ...

Understand the similarities and differences between senile osteoporosis and osteoporosis, including their causes, diagnosis, and treatment.

If you want to know who really controls Arcus Biosciences, Inc. (NYSE:RCUS), then you'll have to look at the makeup of its share registry. With 51% stake, institutions possess the maximum shares ...

There's been a notable change in appetite for Arcus Biosciences, Inc. (NYSE:RCUS) shares in the week since its annual report, with the stock down 11% to US$9.88. Revenue hit US$258m in line with ...

Gilead will not move forward with Arcus Biosciences’ casdatifan, an investigational HIF-2a blocker that is being tested for kidney cancer. As per the California biotech’s Tuesday press announcement, ...